First Wave BioPharma, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 4.07 million compared to USD 9.63 million a year ago. Basic loss per share from continuing operations was USD 36.4.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 USD | -2.91% |
|
-15.02% | -52.15% |
05-20 | Entero Therapeutics, Inc.(NasdaqCM:ENTO) added to NASDAQ Composite Index | CI |
05-17 | First Wave BioPharma, Inc. will Change its Name to Entero Therapeutics, Inc | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-52.15% | 5.12M | |
+39.92% | 53.67B | |
+33.67% | 38.86B | |
-7.85% | 38.76B | |
-10.77% | 27.27B | |
+12.05% | 25.91B | |
-17.54% | 20.29B | |
+34.58% | 12.78B | |
+29.69% | 12.18B | |
-3.06% | 11.96B |
- Stock Market
- Equities
- ENTO Stock
- News Entero Therapeutics, Inc.
- First Wave BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023